ImmunityBio receives FDA authorisation for Phase I Covid-19 vaccine trial

The vaccine can deliver both outer spike and inner nucleocapsid antigens from SARS-CoV-2. Credit: PIRO4D on Pixabay.



  • ImmunityBio